Purpose: We present the largest study of both peripheral blood and lymph node samples examining the utility of reverse transcription-polymerase chain reaction (RT-PCR) for established molecular markers as a diagnostic tool in the molecular staging of prostate cancer patients undergoing radical prostatectomy.
INTRODUCTION
Prostate cancer is the most common noncutaneous malignancy of men in the United States with approximately 198,100 cases and 31,500 deaths occurring in 2001 (1) .
Despite extensive research, it remains difficult to discriminate preoperatively between patients with locally confined prostate cancer and patients with extraprostatic disease. This is demonstrated by the fact that more than one third of men with clinically localized prostate cancer have extraprostatic disease at the time of surgery (2) . Extensive screening using serum prostate-specific antigen (PSA) has led to earlier detection of the disease, and most tumors are now recognized at an organconfined stage (3) . To date, a combination of digital rectal examination, PSA serum levels, and needle biopsy are the basis of preoperative staging and can help to decrease the incidence of pathologic upstaging (4) . However, significant inaccuracies in preoperative staging remain. It has been known that hematogeneous dissemination of tumor cells occurs in cancer as well as in in vivo models (5) . Efforts to develop molecular approaches to detect disseminating tumor cells of solid tumors in peripheral blood or bone marrow, and to correlate the detection with respect to diagnosis, prognostic value, and clinical monitoring, are under investigation (6) .
Two groups initially reported the use of reverse transcription polymerase chain reaction (RT-PCR) to study prostate cancer micrometastasis; tissue sources for PCR analysis included peripheral blood, bone marrow, and pelvic lymph nodes (7, 8) . RT-PCR of histologically cancer-free pelvic lymph nodes from patients undergoing radical lymphadenectomy seems to be particularly promising. Potential molecular markers are PSA, prostate-specific membrane antigen (PSMA), and human kallikrein-2 (hK2). Unfortunately, the published studies have yielded conflicting and controversial results (9 -11) .
A major argument for the use of RT-PCR is the fact that clinically and pathologically localized prostate cancer has a significant chance of biochemical failure after radical retropubic prostatectomy, even for low-grade cancer with all margins and lymph nodes histopathologically negative. RT-PCR might de-tect truly clinically occult metastases and may account for disease recurrence of patients initially diagnosed with localized cancer. A recent study failed to correlate preoperative RT-PCR for PSA and PSMA results with biochemical failure or pathologic stage in 141 patients with localized prostate cancer (12) .
In our study, we examined the expression of all three established molecular markers (PSA, PSMA, and hK2) in the peripheral blood of 358 consecutive patients for preoperative staging and correlated the results with clinical data. In addition, RT-PCR for PSA and hK2 was performed in corresponding 153 lymph node samples. As the hypogastric obturatory lymph nodes are believed to be the first lymph nodes involved in metastatic prostate cancer, we examined this lymph node station regarding micrometastatic spread (13) . We did not include PSMA RT-PCR in our lymph node analysis because it is not exclusively expressed in the prostate (14) . Specifically, we will address whether all three markers are superior versus a single marker, whether lymph node RT-PCR results correlate with clinical variables more accurately than do peripheral blood RT-PCR data, and whether there is any association between peripheral blood and lymph node results.
PATIENTS AND METHODS
From December 1997 to February 2000, 358 patients with biopsy-proven prostate cancer treated at the Urology Department of the Klinikum Offenbach were enrolled in this study. In addition, 45 healthy volunteers, without prior history of a malignancy or any urologic disease, as well as 10 prostate cancer patients with advanced distant metastasis, were recruited in November and December 1997. All of the prostate cancer patients received 3 months of neoadjuvant hormonal ablation therapy with leuprorelide acetate. Informed consent was obtained from all of the participating patients and volunteers, and the protocol was approved by the institutional review board. Blood samples were drawn preoperatively between 7:00 a.m. and 9:00 a.m. before any diagnostic manipulation such as digital rectal examination or transrectal ultrasound imaging. Processing took place immediately, without storage or delay in the urological research laboratory. The serum PSA level was determined for all patients at diagnosis by using the Hybritech assay (Hybritech Inc., San Diego, CA).
In a subgroup of 153 patients, lymph node samples of the obturatory lymph nodes were obtained during radical lymphadenectomy before radical retropubic prostatectomy and were cut in half. One part was snap-frozen in liquid nitrogen, and the other was used for histopathologic evaluation. Prostatic tumor tissue from 20 patients was collected during surgery for sensitivity experiments and were used as control.
Pathologic stages were determined following the TNM (tumor-node-metastasis) classification system. Grading was performed according to WHO guidelines. Roughly, grade 1 tumors relate to Gleason score 2-4, grade 2 tumors to Gleason 5-6/7 and grade 3 tumors to . Detailed pathologic data of all of the patients included in this study are shown in Table 1 .
Cell Lines. The LNCaP cell line [American Type Cell Collection (ATCC) no. CRL 1740] is derived from a human lymph node metastatic prostate cancer (15) . It is a well-established cell line model that expresses PSA, hK2, and PSMA. The cells were cultured in RPMI 1640, supplemented with 4 mmol/L L-glutamine, 10% fetal bovine serum, 100 units/mL penicillin, and 100 g/mL streptomycin, and served as positive control in the sensitivity experiments.
Isolation of Mononuclear Cells from Peripheral Blood and RNA Extraction. The nucleated cell fraction was isolated from 5 ml of whole blood in EDTA with a Percoll gradient (Pharmacia, Freiburg, Germany) centrifugation according to the manufacturer's description. Total RNA was isolated with the RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer's description, immediately snap-frozen, and stored at Ϫ70°C until further processing. Total RNA from snap-frozen lymph node samples was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA).
Reverse Transcription. Total RNA (1.5 g) and 0.5 g of oligo d(T) (Promega, Heidelberg, Germany) in a total volume of 11 L were incubated for 10 min at 70°C and were immediately cooled on ice. To each RNA sample, 4 L of reaction buffer (Promega) consisting of 250 mmol/L Tris-HCl (pH 7.
, and 1 L of M-MLV reverse transcriptase (Promega) were added, shortly centrifuged and subsequently incubated at 37°C for 90 minutes. Final cDNA was stored at Ϫ20°C or was immediately used for amplification by PCR.
PCR and Nested PCR. All of the primers used in this study were custom designed by MWG-Biotech (Ebersberg, Germany). Intron spanning primer pairs specific for human PSA (NM_001648) were sense, 5Ј-GCG TGA TCT TGC TGG GTC GG-3Ј, and antisense, 5Ј-CCT TCT GAG GGT GAA CTT GCG-3Ј. The antisense primer was replaced by 5Ј-AGA ATC ACC CGA GCA GGT GCT-3Ј for nested PCR. Intron spanning primer pairs specific for human PSMA (NM_004476) were for sense, 5Ј-TCA CCG GGA CTC ATG GGT GT-3Ј, and antisense, 5Ј-GCC TGA AGC AAT TCC AAG TCG-3Ј; sense (nested PCR), 5Ј-AAG GAA GGG TGG AGA CCT AG-3Ј, and antisense (nested PCR), 5Ј-ACT GAA CTC TGG GGA AGG AC-3Ј). Intron spanning primer pairs specific for hK2 [Kawakami et al. (21) , NM_005551], were sense, 5Ј-GGT GGC TGT GTA CAG TCA TGG AT-3Ј, and antisense, 5Ј-ACA CAC TGA AGA CTC CTG GGG CG-3Ј; antisense primer was replaced for nested PCR by 5Ј-TGT CTT CAG GCT CAA ACA GGT TG-3Ј). Primers for amplification of the housekeeping gene glyceraldehyde-3-phosphate-dehydrogenase (GAPDH; NM_002046) were sense, 5Ј-CGT CTT CAC CAC CAT GGA GA-3Ј, and antisense, 5Ј-CGG CCA TCA CGC CAC AGT TT-3Ј); and they served as internal quality control to assess RNA integrity. PCR reactions were performed in a total volume of 50 L containing 1 L of reverse transcription product, RT-PCR Assay Sensitivity. RT-PCR assay sensitivity was determined by dilution of LNCaP cells with peripheral blood mononuclear cells of a negative control patient. Peripheral blood mononuclear cells (PBMCs) were isolated as described above and were counted. LNCaP cells were diluted as follows: in PBMCs at 0:10 7 ; at 1:10 7 ; at 10:10 7 ; at 100:10 7 ; and at 1000:10 7 . RNA isolation and RT-PCR were performed as described above.
Analysis of PCR Products. Ten L of PCR product were mixed with 2 L of 6ϫ loading dye (MBI Fermentas, Heidelberg, Germany) and were assayed for 60 minutes on a 1.5% agarose gel in TBE buffer [0.1 mol/L Tris (pH 8.4), 90 mmol/L boric acid, and 1 mmol/L EDTA). The gel was stained with ethidium bromide, and the amplicons were visualized with a UV-transilluminator. Samples were subjected to Southern blot hybridization with digoxigenin-labeled probes to confirm product identity. Representative amplicons were commercially sequenced (SeqLab, Göttingen, Germany).
Statistical Analysis. Kolmogorov-Smirnoff test was applied to test for normal distribution.
5 P values were calculated by Mann-Whitney test, Student's t test, or 2 test.
RESULTS
Sensitivity and Specificity of PSA-, hK2-, and PSMAnested RT-PCR. Control RT-PCR for GAPDH confirmed the integrity of the isolated RNA in all of the samples. To test whether or not marker transcripts are constitutively expressed in prostate cancer tissues, we applied our RT-PCR assay for PSA, hK2, and PSMA to prostate cancer tissue from prostatectomy specimens in 20 patients. As expected, all of the tissues that were analyzed were positive for each of the three markers (data not shown). The sensitivity assays revealed that mRNA for PSA, hK2, and PSMA from an average of 10 LNCaP cells diluted in 10 7 PBMCs could be detected after nested RT-PCR in initially negative control PBMCs from healthy donors. These sensitivity results are comparable with the published reports for which RT-PCR was used (10) .
In another control group of 10 patients with proven distant metastatic prostate cancer, 8 (80%), 7 (70%), and 9 (90%) were positive for PSA, hK2, and PSMA expression by RT-PCR in peripheral blood, respectively. Specificity testing of the markers used in the control group consisting of 45 healthy male volunteers showed false-positive results in peripheral blood RT-PCR for PSA in 3 (6.7%) of 45, for hK2 in 0 (0%) of 45, and for PSMA in 2 (4.5%) of 45.
RT-PCR Results in Peripheral Blood
Samples. An overview of the general positivity rates for PSA, PSMA, and hK2 is given in Table 2 The combination of PSA and hK2 did not show any statistical difference in the groups, whereas a triple marker analysis resulted in a P value of 0.053 in the 2 test [for grade 1, 3 (4.8%) of 63; for grade 2, 12 (5.7%) of 209; for grade 3, 10 (11,6%) of 86]. Table 4 shows the comprehensive result.
RT-PCR Results in Lymph Node Samples. In the subgroup of 153 patients from whom lymph node samples could be 5 SPSS software version 7.5.2 from SPSS Inc., Chicago, IL, 1999. Table 5 .
Among 100 of 153 patients with a tumor stage of pT 2 or less, 56 (56%) were PSA positive, 68 (68%) were hK2 positive, 48 (48%) were positive for both markers (double positive), and 27 (27%) were negative for both markers (double negative). Among 53 of 153 patients with a tumor stage of pT 3 or higher, 26 (49%) were PSA positive, 25 (47%) were hK2 positive, 18 (34%) were double positive, and 20 (38%) were double negative.
In this subgroup, the PSA-, hK2-, and PSA ϩ hK2 RT-PCR-positivity rates of the patients with pT 2 tumors (n ϭ 100) versus the patients with pT 3 or higher (n ϭ 53) were 56 (56%) of 100 versus 26 (49%) of 53 for PSA, 68 (68%) of 100 versus 25 (47%) of 53 for hK2, and 48 (48%) of 100 versus 18 (34%) of 53 for combined PSA ϩ hK2, respectively.
Association of Lymph Node and Peripheral Blood RT-PCR. We were especially interested in a possible association between lymph node and blood RT-PCR results in the group of patients with pN 0 disease. We, therefore, analyzed all of the possible marker combinations. The detailed results of this analysis, which leads to multiple permutations, are given in Table 6 .
Interestingly, PSA-RT-PCR lymph node-positive patients were significantly more often positive in the blood PSA RT-PCR than were lymph node-negative patients (43. 8 
DISCUSSION
Precise preoperative clinical staging of prostate cancer remains difficult, and new prognostic factors are clearly needed (16). These factors should define the aggressive and metastatic potential of early prostate cancer and ideally predict the clinical outcome (17) . A major problem in anticipating the clinical course of prostate carcinoma is highlighted by the fact that the frequency of detecting lymph node metastasis by routine pathological analysis is not associated with the frequency of disease recurrence after radical prostatectomy (18) . RT-PCR might be a promising tool in achieving progress in this difficult field.
The use of RT-PCR for clinical monitoring of prostate cancer patients and detection of disseminating prostate cancer has been under investigation for almost 10 years, but the published results are still controversial. Different studies have shown that RT-PCR is able to detect circulating PSA-, hK2-, and PSMA-expressing cells, not only in patients with systemic disease but also in patients with clinically localized disease (19 -22) .
Few studies have shown a correlation between RT-PCR and pathologic stage or prognostic value, specifically survival duration (23) (24) (25) (26) . In reports critically summarizing the literature on the use of RT-PCR to preoperatively predict extra prostatic disease and PSA recurrence after radical retropubic prostatectomy, the authors argue that additional studies regarding the clinical utility of RT-PCR in prostate cancer patients are needed (9, 27) . Quantitative approaches to detect micrometastatic circulating cells, including expression levels, are thought to improve on the results (observed as simply positive or negative) obtained with standard RT-PCR assays (28) . Despite a trend toward a higher PSA-RT-PCR positivity in peripheral blood in pT 3 cancer patients (40.0 versus 31.9%; P ϭ 0.13, 2 analysis), in concordance with the vast majority of studies published thus far, we were not able to show that RT-PCR analysis by triple markers or any possible permutations could stratify patients with localized cancers to patients with extraprostatic disease. The fact that PSA-RT-PCR is significantly more often positive in high-grade tumors (41%) than in the group of low-(32%) and intermediate-grade cancers (33%) as well as the increase of statistical significance when analyzing a combination of PSA and PSMA-RT-PCR results (17% double positivity in low and intermediate grade versus 28% in high-grade cancers) is promising. Interestingly, a study also found an improvement of RT-PCR significance when combining PSA and PSMA RT-PCR results of peripheral blood and extracapsular penetration (24) .
Encouraging results using RT-PCR to detect micrometastasis in histologically cancer-free lymph nodes were published (29, 30) . Deguchi et al. (29) pioneered the use of PSA RT-PCR on lymph nodes. The number of analyzed samples was small (22 patients), This study is the first to analyze lymph node samples from a large defined patient cohort by RT-PCR for hK2 and PSA, associate these findings with clinical variables, and combine the results of three markers (PSA, PSMA, and hK2) in peripheral blood. Disappointingly, hK2 does not add any value to RT-PCR-based prostate cancer evaluation. As with all other results presented in this study, further follow-up of hK2 lymph node RT-PCR-positive patients has to be awaited. Additionally, the triple-marker evaluation in peripheral blood does not seem to be of value and revealed basically the same observation as the PSA/PSMA RT-PCR study presented recently (12) .
One could argue that the results presented in this study may have been compromised by the fact that patients received neoadjuvant antiandrogen therapy. It was found that patients who had pT 2 and pT 3 tumors and who were treated with neoadjuvant hormones were less likely to have circulating PSMA-positive cells in their peripheral blood, compared with those in the nontreated control group, before and after surgery (32) . In concordance with this finding, it was reported that the hormonetreated group showed a significantly lower incidence of preoperative PSA mRNA positivity than did the group undergoing surgery alone (20 versus 69%, P ϭ 0.036; ref. 33 ). However, a recent study that compared hormone-treated versus untreated patients did not find any difference in RT-PCR positivity in peripheral blood or in bone marrow (34) . Our overall positivity rates for PSA, hK2, and PSMA do not differ much from results of other studies, in which patients have not been treated hor- 
